Tags
- A
- Adopted
- Adult
- Adverse
- AIM
- Alteration
- Alterations
- An
- Approved
- Arm
- Based on
- Bladder
- Bladder cancer
- Cancer
- Carcinogenesis
- Carcinoma
- Characteristic
- Chemotherapy
- Clinical
- Clinical endpoint
- Clinical outcomes
- Cohort
- Combination therapy
- Committee for Medicinal Products for Human Use
- Containment
- Content
- Content editor
- Cut-off
- Data
- DDW
- Death
- Decisions
- Demonstrate
- Diagnosis
- Diana Spencer
- Digital
- Digital content
- Discovery!
- Discovery World
- Disease
- Driver
- Drug
- Drug discovery
- Editor
- Ema Ha
- Enabling
- Erdafitinib
- Europe
- European
- European Medicines Agency
- Fibroblast growth factor receptor
- Fibroblast growth factor receptor 3
- France
- Genetic
- Gustave Roussy
- Highest
- Human subject research
- If
- Indoor Living
- Inhibitor
- Institut Gustave Roussy
- Janssen-Cilag
- Loriot
- Marking
- Medicine
- Metástasis
- Most
- Need
- Novel
- One Line
- One Year
- Over
- Paris-Saclay
- Patient
- PD-L1
- PD-L1 inhibitor
- Pharmaceutical drug
- Phase
- Phase III
- Polymorphism
- Positive
- Product
- Programmed cell death protein 1
- Progression-free survival
- Recommendation
- Recommended
- Reduction
- Representin'
- Response rate
- Result
- Risk
- Roussy-le-Village
- Survival
- Survival rate
- Susceptible individual
- Targeted
- Targeted therapy
- Targeting
- The european
- The first
- Therapy
- The world
- Tithe
- Transitional cell carcinoma
- Treat
- Treatment outcome
- Treatment outcomes
- University
- University of Paris-Saclay
- Urothelium
- V
- Versus
- Who